Christopher Maisel

405 total citations
20 papers, 127 citations indexed

About

Christopher Maisel is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Christopher Maisel has authored 20 papers receiving a total of 127 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 10 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Christopher Maisel's work include Multiple Myeloma Research and Treatments (17 papers), Protein Degradation and Inhibitors (7 papers) and Peptidase Inhibition and Analysis (5 papers). Christopher Maisel is often cited by papers focused on Multiple Myeloma Research and Treatments (17 papers), Protein Degradation and Inhibitors (7 papers) and Peptidase Inhibition and Analysis (5 papers). Christopher Maisel collaborates with scholars based in United States, Spain and France. Christopher Maisel's co-authors include Nizar J. Bahlis, Lili Liu, Stanton L. Gerson, Barry Cooper, Joseph W. Fay, Estil Vance, R.B. Berryman, Edward Agura, Houston Holmes and Scot C. Remick and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Christopher Maisel

19 papers receiving 126 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher Maisel United States 7 89 79 53 17 15 20 127
Ravi Vij United States 4 137 1.5× 117 1.5× 60 1.1× 9 0.5× 11 0.7× 13 171
José-María Arguiñano Spain 2 125 1.4× 104 1.3× 55 1.0× 9 0.5× 15 1.0× 4 128
Laura Rosiñol Spain 5 152 1.7× 94 1.2× 89 1.7× 8 0.5× 29 1.9× 18 159
C. Hulin France 6 161 1.8× 141 1.8× 92 1.7× 5 0.3× 20 1.3× 16 188
Laurène Fenwarth France 6 56 0.6× 39 0.5× 14 0.3× 20 1.2× 17 1.1× 19 92
María Ángeles Montalbán Spain 4 125 1.4× 81 1.0× 51 1.0× 10 0.6× 44 2.9× 7 146
Adele Baker Australia 3 87 1.0× 155 2.0× 60 1.1× 9 0.5× 11 0.7× 3 186
Ana-Isabel Teruel Spain 3 175 2.0× 140 1.8× 84 1.6× 4 0.2× 26 1.7× 3 181
Kalyan Nadiminti United States 6 68 0.8× 65 0.8× 24 0.5× 6 0.4× 18 1.2× 24 115
Aino‐Maija Leppä Germany 3 101 1.1× 75 0.9× 14 0.3× 16 0.9× 28 1.9× 10 129

Countries citing papers authored by Christopher Maisel

Since Specialization
Citations

This map shows the geographic impact of Christopher Maisel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Maisel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Maisel more than expected).

Fields of papers citing papers by Christopher Maisel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Maisel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Maisel. The network helps show where Christopher Maisel may publish in the future.

Co-authorship network of co-authors of Christopher Maisel

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Maisel. A scholar is included among the top collaborators of Christopher Maisel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Maisel. Christopher Maisel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Manier, Salomon, Alexander M. Lesokhin, Mohamad Mohty, et al.. (2023). P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES. HemaSphere. 7(S3). e26808c7–e26808c7. 3 indexed citations
2.
Nooka, Ajay K., Alexander M. Lesokhin, Mohamad Mohty, et al.. (2023). EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN–DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES. Hematology Transfusion and Cell Therapy. 45. S405–S405. 1 indexed citations
3.
Touzeau, Cyrille, Nizar J. Bahlis, Christopher Maisel, et al.. (2023). P907: EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3. HemaSphere. 7(S3). e16622f0–e16622f0. 3 indexed citations
4.
Bahlis, Nizar J., Suzanne Trudel, Christopher Maisel, et al.. (2023). Safety of Elranatamab in Patients with Triple-Class Refractory Relapsed/Refractory Multiple Myeloma (RRMM) in Magnetismm-17, a North American Expanded Access Protocol. Blood. 142(Supplement 1). 6737–6737.
5.
Larson, Sarah M., Nizar J. Bahlis, Christopher Maisel, et al.. (2023). Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3.. Journal of Clinical Oncology. 41(16_suppl). e20017–e20017. 1 indexed citations
6.
Nooka, Ajay K., Alexander M. Lesokhin, Mohamad Mohty, et al.. (2023). Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.. Journal of Clinical Oncology. 41(16_suppl). 8008–8008. 21 indexed citations
7.
Larocca, Alessandra, Xavier Leleu, Cyrille Touzeau, et al.. (2021). Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. British Journal of Haematology. 196(3). 639–648. 8 indexed citations
8.
Rodríguez‐Otero, Paula, María‐Victoria Mateos, Albert Oriol, et al.. (2021). Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.. Journal of Clinical Oncology. 39(15_suppl). 8048–8048. 1 indexed citations
9.
Mateos, María‐Victoria, Albert Oriol, Alessandra Larocca, et al.. (2020). HORIZON (OP-106): An exploratory analysis of time-to-next treatment (TTNT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) who received melflufen plus dexamethasone (dex).. Journal of Clinical Oncology. 38(15_suppl). e20570–e20570. 4 indexed citations
10.
11.
12.
Richardson, Paul G., Albert Oriol, Alessandra Larocca, et al.. (2019). S1605 HORIZON (OP‐106): UPDATED EFFICACY AND SAFETY OF MELFLUFEN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO DARATUMUMAB (DARA) AND/OR POMALIDOMIDE (POM). HemaSphere. 3(S1). 739–739. 1 indexed citations
13.
Richardson, Paul G., Albert Oriol, Alessandra Larocca, et al.. (2019). HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and Safety. Clinical Lymphoma Myeloma & Leukemia. 19. S329–S330. 2 indexed citations
14.
Richardson, Paul G., María‐Victoria Mateos, Paula Rodríguez‐Otero, et al.. (2019). Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population. Clinical Lymphoma Myeloma & Leukemia. 19(10). e352–e353. 2 indexed citations
15.
Richardson, Paul G., Enrique M. Ocio, Albert Oriol, et al.. (2018). OP-106 Horizon — Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS. Blood. 132(Supplement 1). 600–600. 11 indexed citations
16.
Levy, Yair, et al.. (2014). Haematological complete remission by ponatinib and bortezomib in a patient with relapsed, Ph+ pre-B acute lymphoblastic leukaemia. BMJ Case Reports. 2014. bcr2014203894–bcr2014203894. 1 indexed citations
17.
18.
Maisel, Christopher, Lili Liu, Pingfu Fu, et al.. (2007). O6-benzylguanine and BCNU in multiple myeloma: a phase II trial. Cancer Chemotherapy and Pharmacology. 60(3). 415–421. 23 indexed citations
19.
Agura, E.D., R.B. Berryman, Breanna Cooper, et al.. (2007). Phase II study of clofarabine and cytosine arabinoside in adult patients with relapsed AML and in elderly patients with untreated AML who are at high risk of anthracycline toxicity. Journal of Clinical Oncology. 25(18_suppl). 7064–7064. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ravi Vij Breakdown of academic impact, for papers by José-María Arguiñano Breakdown of academic impact, for papers by Laura Rosiñol Breakdown of academic impact, for papers by C. Hulin Breakdown of academic impact, for papers by Laurène Fenwarth Breakdown of academic impact, for papers by María Ángeles Montalbán Breakdown of academic impact, for papers by Adele Baker Breakdown of academic impact, for papers by Ana-Isabel Teruel Breakdown of academic impact, for papers by Kalyan Nadiminti Breakdown of academic impact, for papers by Aino‐Maija Leppä
Rankless by CCL
2026